Integrating Novel Microtubule-Stabilizing Agents for the Treatment of Chemorefractory Advanced Breast Cancer Patients CME

Author Information and Disclosures

Release Date: July 10, 2008; Valid for credit through July 10, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

This CME activity, “Integrating Novel Microtubule-Stabilizing Agents for the Treatment of Chemorefractory Advanced Breast Cancer Patients,” was created to be distributed on Medscape.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 SciMed. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of SciMed is prohibited.
BMS
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the mechanistic differences between taxanes and epothilones.
  2. Discuss the efficacy and safety of epothilones and other treatment options for women with locally recurrent or metastatic BC.
  3. Assess the role of epothilones in combination with other chemotherapeutic agents.
  4. Develop a plan for managing common adverse events associated with the use of epothilones.
Authors and Disclosures

Linda T. Vahdat, MD
Disclosure: Grant/Research Support: Berlex Laboratories, Bristol-Myers Squibb Company, Eisai Pharmaceuticals, Pfizer Inc


Tiffany Traina, MD
Disclosure: Dr Traina has no relevant conflicts to report.
 
SciMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SciMed designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.